Analyst Builds Bullish Case For This Neuromuscular Company, Sees 200% Upside

  • HC Wainwright has assumed coverage on Scholar Rock Holding Corp SRRK with a Buy rating and price target of $30.
  • The analyst writes that with a positive readout from the Phase 2 TOPAZ study under their belt, Scholar Rock’s apitegromab (SRK-015) is shaping to be a transformative therapeutic for Type 2/3 Spinal Muscular Atrophy (SMA). 
  • HC Wainwright says that recent 24-Month TOPAZ extension data further convinces that apitegromab can solidify a place in the SMA market (2025 est. approval) by being a muscle-directed therapy that can complement current SMN therapies. 
  • Apitegromab showed a mean HFMSE change of +4.4 points, with 81% of patients achieving a ≥1 point increase and 56% achieving ≥3 points. 
  • Scholar Rock is currently enrolling patients for its pivotal Phase 3 SAPPHIRE study, which KOLs indicate may deliver equal, if not better results, as the design is influenced by TOPAZ. 
  • Price Action: SRRK shares are up 2.75% at $9.16 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetSmall CapAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!